5.6.7. intracavernous injections therapy. intracavernous administration vasoactive drugs first medical treatment introduced ed . patients may offered intracavernous injections every stage tailored treatment work-up. 5.6.7.1. alprostadil alprostadil (caverjecttm, edex/viridaltm) first drug approved intracavernous treatment ed . intracavernous alprostadil efficacious monotherapy dose 5-40 μg (40 μg may offered off-label european countries). erection appears 5-15 minutes lasts according dose injected, significant heterogeneity among patients. office-training programme required patients learn injection technique. efficacy rates intracavernous alprostadil > 70% found general ed population, well patient subgroups (e.g., men diabetes cvd), reported satisfaction rates 87-93.5% patients 86-90.3% partners injections . complications intracavernous alprostadil include penile pain (50% patients reported pain 11% total injections), excessively prolonged undesired erections (5%), priapism (1%), fibrosis (2%) . pain usually self-limited prolonged use alleviated addition sodium bicarbonate local anaesthesia . cavernosal fibrosis usually clears within months temporary discontinuation injection programme. however, tunical fibrosis suggests early onset peyronie’s disease may indicate need discontinue intracavernous injections indefinitely. systemic adverse effects uncommon. common mild hypotension, especially using higher doses. contraindications include men history hypersensitivity alprostadil, men risk priapism, men bleeding disorders. despite favourable data, drop-out rates 41-68% reported intracavernous pharmacotherapy , discontinuations occurring within first two three months. careful counselling patients office-training phase well close follow-up important addressing patient withdrawal intracavernous injection programme [424-426]. 5.6.7.2. vasoactive intracavernous treatments table 12 details available intracavernous injection therapies (compounds characteristics). combination therapy enables patient take advantage different modes action drugs used, well alleviating adverse effects using lower doses drug. papaverine (20-80 mg) first oral drug used intracavernous injections. commonly used combination therapy high incidence adverse effects monotherapy. papaverine currently licensed treatment ed.phentolamine used combination therapy increase efficacy. monotherapy, produces poor erectile response. phentolamine currently licensed treatment ed.limited data support use drugs, vasoactive intestinal peptide (vip), donors (linsidomine), forskolin, potassium channel openers, moxisylyte calcitonin gene-related peptide, usually combined main drugs . combinations standardised drugs limited availability worldwide.bimix, (papaverine 7.5-45 mg plus phentolamine 0.25-1.5 mg) trimix (papaverine 8-16 mg plus phentolamine 0.2-0.4 mg plus alprostadil 10-20 μg), widely used improved efficacy rates, although never licensed ed . trimix highest efficacy rates, reaching 92%; combination similar adverse effects alprostadil monotherapy, lower incidence penile pain due lower doses alprostadil. however, fibrosis common (5-10%) papaverine used (depending total dose).invicorptm: vasoactive intestinal peptide (25 μg) plus phentolamine mesylate (1-2 mg invicorp), combination two active components complementary modes action. clinical studies shown combination effective intracavernous injections > 80% men ed, including failed respond therapies and, unlike existing intracavernous therapies, associated low incidence penile pain virtually negligible risk priapism . overall, despite high efficacy rates, 5-10% patients respond combination therapy intracavernous injections. table 12: intracavernous injection therapy - compounds characteristics namesubstancedosageefficacyadverse eventscommentcaverject™ edex/viridal™alprostadil5-40 μg/ml~ 70%penile pain, priapism, fibrosiseasily availablepapaverinepapaverine20 - 80 mg< 55%elevation liver enzymes, priapism, fibrosisabandoned monotherapyphentolaminephentolamine0.5 mg/mlpoor efficacy monotherapysystemic hypotension, reflex tachycardia, nasal congestion, gastrointestinal upsetabandoned monotherapybimixpapaverine + phentolamine30 mg/ml +0.5 mg/ml~ 90%similar alprostadil (less pain)not licensed treatment edtrimixpapaverine + phentolamine + alprostadil30 mg/ml +1 mg/ml +10 μg/ml~ 92%similar alprostadil (less pain)not licensed treatment edinvicorp™vasoactive intestinal peptide (vip) + phentolamine25 μg + 1-2 mg~ 80%similar alprostadil without paineasily available